Rolf P Mueller
Overview
Explore the profile of Rolf P Mueller including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
276
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
von Tresckow B, Plutschow A, Fuchs M, Klimm B, Markova J, Lohri A, et al.
J Clin Oncol
. 2012 Jan;
30(9):907-13.
PMID: 22271480
Purpose: In patients with early unfavorable Hodgkin's lymphoma (HL), combined modality treatment with four cycles of ABVD (adriamycin, bleomycin, vinblastine, and dacarbazine) and 30 Gy involved-field radiotherapy (IFRT) results in...
2.
Warnecke-Eberz U, Metzger R, Bollschweiler E, Baldus S, Mueller R, Dienes H, et al.
Pharmacogenomics
. 2009 Dec;
11(1):55-64.
PMID: 20017672
Aims: Neoadjuvant radiochemotherapy of locally advanced esophageal cancer is only effective for patients with major histopathological response. A total of 17 genes were selected to predict histopathologic tumor response to...
3.
Ling F, Leimbach N, Baldus S, Buechel S, Neiss S, Brabender J, et al.
Anticancer Res
. 2007 Jan;
26(6B):4505-9.
PMID: 17201171
Background: Hypoxia-inducible factor-1alpha (HIF-1alpha) expression was reported to be associated with tumor growth, progression and resistance to radio-/chemotherapy. Whether HIF-1alpha mRNA or protein expression is associated with histomorphological response or...
4.
Prenzel K, Konig A, Schneider P, Schnickmann C, Baldus S, Schroder W, et al.
Ann Surg Oncol
. 2006 Nov;
14(2):954-9.
PMID: 17103071
Background: Neoadjuvant treatment modalities for esophageal cancer were developed to improve local tumor control as well as to reduce lymph node metastases and distant metastases in patients with locally advanced...
5.
Xi H, Baldus S, Warnecke-Eberz U, Brabender J, Neiss S, Metzger R, et al.
Clin Cancer Res
. 2005 Dec;
11(23):8341-7.
PMID: 16322294
Purpose: High expression of cyclooxygenase-2 (COX-2) was shown to inhibit chemotherapy- and radiotherapy-induced apoptosis. We analyzed the association of COX-2 mRNA and protein expression with histomorphologic response to neoadjuvant radiochemotherapy...
6.
Schneider P, Baldus S, Metzger R, Kocher M, Bongartz R, Bollschweiler E, et al.
Ann Surg
. 2005 Oct;
242(5):684-92.
PMID: 16244542
Objective: We sought to quantitatively and objectively evaluate histomorphologic tumor regression and establish a relevant prognostic regression classification system for esophageal cancer patients receiving neoadjuvant radiochemotherapy. Patients And Methods: Eighty-five...
7.
Warnecke-Eberz U, Hokita S, Xi H, Higashi H, Baldus S, Metzger R, et al.
Oncol Rep
. 2005 May;
13(6):1241-6.
PMID: 15870949
Survivin is a member of the inhibitor of apoptosis (IAP) gene family known to be involved in resistance to chemo- and radiation therapy. We examined the potential of quantitative survivin...
8.
Warnecke-Eberz U, Metzger R, Miyazono F, Baldus S, Neiss S, Brabender J, et al.
Clin Cancer Res
. 2004 Jun;
10(11):3794-9.
PMID: 15173087
Purpose: The excision repair cross-complementing 1 (ERCC1) gene is coding for a nucleotide excision repair protein involved in the repair of radiation- and chemotherapy-induced DNA damage. We examined the potential...